PCR-based detection of an emerging avian pneumovirus in US turkey flocks

Detection of Three Avian Respiratory Viruses by Single-Tube Multiplex Reverse Transcription–Polymerase Chain Reaction Assay

Acute respiratory tract infections are leading causes of morbidity in poultry farms throughout the world. Avian pneumovirus (APV), avian influenza virus (AIV), and Newcastle disease virus (NDV) have been recognized as the most important pathogens of both chicken and turkeys. Single-virus reverse transcription–polymerase chain reaction (sRT-PCR) assays are used extensively to detect these viruses in clinical samples. This study reports the development and evaluation of a single-tube multiplex RT-PCR (mRT-PCR) assay for simultaneous and specific detection of APV, AIV, and NDV. Specific primers for each virus were selected that amplified products of predicted sizes from each virus in the mRT-PCR as well as in the sRT-PCR assays (438, 218, and 532 bp for APV, AIV, and NDV, respectively). The sensitivity and specificity of mRT-PCR assay were compared with those of the sRT-PCR. The mRT-PCR assay was as sensitive as the sRT-PCR assays because virus detection limits were similar in both assays. The detection limits of mRT-PCR assay were 100.5 tissue culture infective dose (50%) (TCID50)/ml, 101.2 TCID50/ml, and 100.7 TCID50/ml for APV, AIV, and NDV, respectively. Overall, there was an excellent correlation between mRT-PCR and sRT-PCR assays. No product amplification was obtained with nucleic acid from infectious bronchitis virus and reovirus using these primer sets. In summary, mRT-PCR assay holds potential to be an economical and rapid diagnostic method for the simultaneous detection of 3 avian respiratory viruses in chickens and turkeys.

Evaluation of Five Different Antigens in Enzyme-Linked Immunosorbent Assay for the Detection of Avian Pneumovirus Antibodies

Five different antigens were evaluated in enzyme-linked immunosorbent assay (ELISA) tests for the detection of avian pneumovirus (APV) antibodies. Two of the 5 antigens were prepared from recent APV isolates from Minnesota. The 2 older isolates were passage 63 of a strain currently used as a live, attenuated vaccine and a Colorado strain isolated for the first time in the United States and currently used in an ELISA test. The fifth antigen is based on an APV recombinant N-protein. Basic parameters and positive-negative threshold of the assays were established for all 5 antigens on the basis of data obtained by testing 46 known negative and 46 known positive serum samples. Subsequently, 449 field samples were tested by all 5 ELISAs. The optical density difference (ODD) was calculated by subtracting optical density of the sample in the negative antigen well from that in the positive antigen well. In the current ELISA test based on the Colorado strain, an ODD of 0.2 is considered to be the cutoff value to classify samples as negative or positive. In this study, however, use of different cutoffs, based on ODD of negative control plus 3 SD or values estimated from Receiver operating characteristic analysis, was considered to be more appropriate for the various antigens used. Overall person-to-person and day-to-day variability was found to be large for all tests using either ODD or sample to positive ratio to report results. In addition, results suggest that antigenicity of the APV isolates in the United States has not changed between 1997 and 2000.

Effect of amino acid sequence variations at position 149 on the fusogenic activity of the subtype B avian metapneumovirus fusion protein

The entry of enveloped viruses into host cells requires the fusion of viral and cell membranes. These membrane fusion reactions are mediated by virus-encoded glycoproteins. In the case of avian metapneumovirus (aMPV), the fusion (F) protein alone can mediate virus entry and induce syncytium formation in vitro. To investigate the fusogenic activity of the aMPV F protein, we compared the fusogenic activities of three subtypes of aMPV F proteins using a TCSD50 assay developed in this study. Interestingly, we found that the F protein of aMPV subtype B (aMPV/B) strain VCO3/60616 (aMPV/vB) was hyperfusogenic when compared with F proteins of aMPV/B strain aMPV/f (aMPV/fB), aMPV subtype A (aMPV/A), and aMPV subtype C (aMPV/C). We then further demonstrated that the amino acid (aa) residue 149F contributed to the hyperfusogenic activity of the aMPV/vB F protein. Moreover, we revealed that residue 149F had no effect on the fusogenic activities of aMPV/A, aMPV/C, and human metapneumovirus (hMPV) F proteins. Collectively, we provide the first evidence that the amino acid at position 149 affects the fusogenic activity of the aMPV/B F protein, and our findings will provide new insights into the fusogenic mechanism of this protein.

Propagation of avian metapneumovirus subtypes A and B using chicken embryo related and other cell systems

Primary isolation of avian metapneumovirus (aMPV) is carried out using tracheal organ culture (TOC) or chicken embryonated eggs with subsequent adaptation in chicken embryo fibroblasts (CEF) or Vero cultures. This study was conducted to evaluate six different cell lines and two avian culture systems for the propagation of aMPV subtypes A and B. The chicken embryo related (CER) cells were used successfully for primary isolation. In addition to Vero and baby hamster kidney (BHK-21) cells, CER cells were also shown to be the most appropriate for propagation of aMPV considering high titres. Propagation of A and B subtypes in CEF and TOC remained efficient after the primary isolation and several passages of viruses in the CER cell line. The growth curves were created using CER, Vero and BHK-21 cell lines. Compared with growth, both yielded higher titres in CER cells during the first 30 h after infection, but no significant difference was observed in the results obtained from CER and Vero cells. This data show that CER cells are adequate for aMPV subtypes A and B propagation, giving similar results to Vero cells.

Permissibility of different cell types for the growth of avian metapneumovirus

Vero cells are commonly used for the growth of avian metapneumovirus subtype C (aMPV-C). This study was conducted to evaluate 17 different cell types for the growth of a Minnesota strain of aMPV-C. The virus was inoculated into these cell types and virus growth was monitored by the development of cytopathic effects (cpe) and immunofluorescence. Virus growth was obtained in 6 of 17 cell types tested with the highest virus titers observed in BGM and DF-1 cells. The flow cytometric analysis of cells at 72 h post inoculation found the highest number of infected cells in BGM cells followed by QT-35 cells. At 48 h post inoculation, DF-1 and BGM cells showed the highest number of infected cells. These results suggest that BGM, QT-35, and DF-1 cells can be used for high titer propagation of aMPV-C.

Avian metapneumovirus phosphoprotein targeted RNA interference silences the expression of viral proteins and inhibits virus replication

Avian metapneumovirus (aMPV) is one of the major causes of serious respiratory infections of poultry and leads to considerable economic losses to food animal production worldwide. Here, we show that double stranded short interfering RNA (siRNA) molecules corresponding to aMPV phosphoprotein (P) gene silence P RNA and protein expression. These siRNAs broadly reduced the expression of other viral proteins in addition to P, but did not have a discernable effect on cellular protein expression. The exposure of cells to P-specific siRNAs also led to inhibition of virus replication as evidenced by marked reduction in the progeny virion titers. Taken together, the findings suggest that exogenous P silencing siRNAs can inhibit aMPV replication with potential implications in the design of novel siRNA based prophylactics.

Growth of vaccine strains of avian pneumovirus in different cell lines

The isolation of avian pneumovirus (APV) (avian metapneumovirus) is usually performed in embryonated chicken eggs or chicken embryo fibroblast cell cultures followed by adaptation in continuous cell lines such as Vero cells. This study was conducted to find a suitable cell line that could be used to propagate vaccine strains of APV to high titre. For this purpose, we compared the growth of two Vero cell-adapted vaccine strains of APV (P63 and ca-APV) in seven different cell types with their growth in Vero cells. The cell types used were BGM-70, MA-104, QT-35, BHK-21, McCoy and DF-1 cells and primary turkey embryo fibroblast cells. When compared with growth in Vero cells, both viruses yielded higher titres in BGM-70 cells, while P63 also produced higher titres in MA-104 cells. In another experiment, the two viruses were grown and titrated in Vero cells under various cell culture conditions, such as age of cells, seeding concentration, and time of harvest. None of these cell culture variables were found to affect virus titres.

Seroprevalence of avian pneumovirus in Minnesota turkeys

Avian pneumovirus (APV) causes respiratory tract infection in turkeys and was first seen in the United States in Colorado in late 1996. In early 1997, the disease was recognized in Minnesota and caused estimated losses of up to 15 million dollars per year. This virus has not been reported in the other turkey producing states. We here report the seroprevalence of APV in Minnesota from August 1998 to July 2002. The average rate of seroprevalence has been 36.3% (range = 14.2%-64.8%). A seasonal bias was observed, with peak incidences in the fall and spring. A higher rate of seropositivity was observed in counties with the highest concentration of turkeys.

Sequence analysis of the matrix (M2) protein gene of avian pneumovirus recovered from turkey flocks in the United States

We here report the comparative sequence and phylogenetic analysis of the avian pneumovirus subgroup C (APV C) matrix (M2) gene of cell culture-adapted isolates and clinical samples. Limited heterogeneity was observed among the M2 sequences, suggesting that diagnostic tests and vaccines against APV C are likely to exhibit broad cross-reactivity.

Effect of an immunomodulator on the efficacy of an attenuated vaccine against avian pneumovirus in turkeys

Since 1997, avian pneumovirus (APV) has caused estimated annual losses of $15 million to the Minnesota turkey industry. In order to develop an attenuated live vaccine against APV, we serially passaged a Minnesota isolate of APV (APV/MN/turkey/1-a/97) in vitro in cell cultures for 41 passages. Laboratory experiments with this high-passage virus (P41) indicated that the attenuated virus provided immunogenic protection to turkeys against challenge with virulent APV, although some birds showed mild to moderate dinical signs after inoculation. To reduce the residual pathogenicity of P41, while maintaining its immunogenicity, we decided to vaccinate turkeys with P41 in the presence of an immunomodulator, S-28828 (1-n-butyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4-amine-hydrochloride), which is a potent cytokine inducer. The combined inoculation of S-28828 (5 mg/kg body weight) and P41 resulted in a significant reduction in the incidence of virus-induced clinical signs in comparison with birds that received P41 without immunomodulator (P < 0.05). Only 17% of birds inoculated with S-28828 + APV P41 showed mild respiratory symptoms at 5 days postinoculation as compared with 46% of the vaccinated turkeys that did not receive S-28828. Vaccination with either P41 or with P41 + S-28828 protected turkeys against dinical signs and viral replication after challenge with virulent APV. These results indicate that immunomodulators, such as S-28828, may act as good vaccine adjuvants that can reduce the pathogenicity but maintain the immunogenicity of partially attenuated vaccines.

Cold adapted avian pneumovirus for use as live, attenuated vaccine in turkeys

We report the development of a cold adapted strain of avian pneumovirus (APV) and its evaluation as a live vaccine candidate in 2-week-old turkey poults. A US isolate of APV (APV/MN/turkey/1-a/97) was serially passaged in Vero cells for 41 passages and then adapted to grow at sub-optimal temperatures by growing successively at 35, 33 and 31 degrees C for eight passages at each temperature. The virus thus adapted to grow at 31 degrees C was used as a candidate vaccine. The birds were vaccinated with two different doses of cold adapted virus and challenged with virulent virus 2 weeks after vaccination. No clinical signs were observed post-vaccination. Upon challenge, no clinical signs were seen in vaccinated birds but severe clinical signs were seen in non-vaccinated, challenged birds. The signs included unilateral or bilateral mucoid nasal discharge, watery eyes and swelling of infraorbital sinuses. The antibody levels in vaccinated birds were not very high. None of the vaccinated birds were found to shed virus after challenge in their choanal secretions whereas all of the non-vaccinated, challenged birds shed the virus. The absence of clinical signs and virus shedding in vaccinated birds as compared to that in non-vaccinated birds suggests that the cold adapted strain of APV is a viable candidate for use as a live, attenuated vaccine in turkeys.

Characterization of avian metapneumoviruses isolated in the USA

Avian pneumovirus (APV; officially known as turkey rhinotracheitis virus) is an emergent pathogen of birds in the USA that results in upper respiratory tract disease in turkeys. Six years after the first outbreak in the USA, the disease continues to ravage turkey flocks, primarily in the state of Minnesota. From 1997 to 2000, the industry recorded losses estimated at 15 million US dollars per annum. Researchers have developed sensitive diagnostic techniques, including the enzyme-linked immunosorbent assay and the reverse transcriptase-polymerase chain reaction. which, when used together, are highly sensitive in detecting APV outbreaks in commercial turkey flocks. Phylogenetic analysis of the nucleotide and predicted amino acid sequence of 15 US viruses isolated between 1996 and 2000 demonstrated that the US viruses are relatively homogenous but different from the European APV subgroups A and B, resulting in the classification of US isolates into subgroup C. Infectious APV was isolated from sentinel waterfowls placed close to an infected commercial turkey farm and from wild Canada geese captured in Minnesota, suggesting that free-ranging birds may be involved in the spread of APV. Current efforts to prevent and control the infection include improving management and biosecurity practices and developing attenuated live and deletion mutant vaccines capable of conferring protection.

A single subtype of avian pneumovirus circulates among Minnesota turkey flocks

The recent emergence of avian pneumovirus (APV) infection among US turkey flocks has resulted in a major economic threat to the turkey industry. In order to elucidate the molecular epidemiology of APV, comparative sequence analysis of the fusion (F) protein gene of APV was performed for 3 cell culture-adapted isolates and 10 APV positive clinical samples recovered from US turkey flocks. Relatively modest levels of nucleotide and amino acid sequence divergence were identified, suggesting the prevalence of a single lineage of APV among US turkey flocks. Additionally, numerous polymorphisms were identified that were only represented in the clinical samples but not in the in vitro propagated isolates of APV. Phylogenetic analyses confirm that the subtype of APV circulating in the upper Midwestern United States is evolutionarily related to, but distinct from, European APV subgroups A and B. Overall, the results of the present investigation suggest that there has been only a single recent introduction of APV into US turkey populations in the upper Midwestern United States.

Experimental and field evaluation of a live vaccine against avian pneumovirus

The attenuation of an avian pneumovirus (APV) isolate (APV/MN/turkey/1-a/97) by 63 serial passages in cell culture (seven in chicken embryo fibroblasts and 56 in Vero cells) and its evaluation as a live attenuated vaccine in turkey poults is described. The birds were vaccinated with two different doses of attenuated virus (10(4.5) median tissue culture infectious dose (TCID(50))/ml and 10(2.5) TCID(50) /ml) at 2 weeks of age, and were challenged 2 weeks later with virulent APV. No clinical signs were seen in vaccinated, challenged birds, whereas severe clinical signs were observed in the mock-vaccinated, challenged group. Vaccinated birds developed anti-APV antibodies, which increased in titre following challenge with virulent virus. On challenge, none of the vaccinates was found to shed viral nucleic acid as detected by reverse transcriptase-polymerase chain reaction, but non-vaccinated, challenged birds did. The vaccine virus was also evaluated under field conditions in two farms. At one farm, the 'seeder bird approach' was used and two birds per 1,000 birds were vaccinated by the oculo-nasal route. In the second farm, the virus was given to all birds simultaneously in the drinking water. The birds vaccinated by the drinking water route seroconverted earlier and continued to shed virus for longer as compared with birds inoculated by the seeder bird approach. The overall results of this study indicate that the 63rd passage of APV was sufficiently attenuated and offered protection against challenge with virulent virus.

Pathogenesis of avian pneumovirus infection in turkeys

Avian pneumovirus (APV) is the cause of a respiratory disease of turkeys characterized by coughing, ocular and nasal discharge, and swelling of the infraorbital sinuses. Sixty turkey poults were reared in isolation conditions. At 3 weeks of age, serum samples were collected and determined to be free of antibodies against APV, avian influenza, hemorrhagic enteritis, Newcastle disease, Mycoplasma gallisepticum, Mycoplasma synoviae, Mycoplasma meleagridis, Ornithobacterium rhinotracheale, and Bordetella avium. When the poults were 4 weeks old, they were inoculated with cell culture-propagated APV (APV/Minnesota/turkey/2a/97) via the conjunctival spaces and nostrils. After inoculation, four poults were euthanatized every 2 days for 14 days, and blood, swabs, and tissues were collected. Clinical signs consisting of nasal discharge, swelling of the infraorbital sinuses, and frothy ocular discharge were evident by 2 days postinoculation (PI) and persisted until day 12 PI. Mild inflammation of the mucosa of the nasal turbinates and infraorbital sinuses was present between days 2 and 10 PI. Mild inflammatory changes were seen in tracheas of poults euthanatized between days 4 and 10 PI. Antibody to APV was detected by day 7 PI. The virus was detected in tissue preparations and swabs of nasal turbinates and infraorbital sinuses by reverse transcription polymerase chain reaction, virus isolation, and immunohistochemical staining methods between days 2 and 10 PI. Virus was detected in tracheal tissue and swabs between days 2 and 6 PI using the same methods. In this experiment, turkey poults inoculated with tissue culture-propagated APV developed clinical signs similar to those seen in field cases associated with infection with this virus.

Sequence analysis of the nucleocapsid and phosphoprotein genes of avian pneumoviruses circulating in the US

Avian pneumovirus (APV) has recently been described as the cause of a new respiratory syndrome in turkey flocks in the United States. We here describe the complete sequence of the nucleocapsid (N) and phosphoprotein (P) genes of this emerging APV (APV/US). Our results show 59 and 61% nucleotide sequence identity of the APV/US N gene with N genes of previously described European APV subgroups A and B, respectively. The P gene of APV/US showed only 53% nucleotide sequence identity with the ortholog from APV subgroup A. Phylogenetic analyses of both N and P genes clearly demonstrate that the APV/US lineage is evolutionarily related but distinct from European APVs. Moreover, sequence analysis of the N and P genes from two laboratory adapted isolates of APV/US (APV/MN-1a and APV/MN-1b) and from ten clinical samples from APV-infected turkeys suggests only modest level of amino acid divergence in the N (0-0.3%) and P (0-1.4%) proteins. Taken together, the results of this study indicate support that APV/US represents a new subgroup (subgroup C) of APV and show that there is limited heterogeneity in the N and P genes of APV/US isolates.